alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1995
<PERIOD-START>                             JAN-01-1995
<PERIOD-END>                               SEP-30-1995
<CASH>                                         642,764
<SECURITIES>                                         0
<RECEIVABLES>                                  506,138
<ALLOWANCES>                                  (58,617)
<INVENTORY>                                          0
<CURRENT-ASSETS>                                     0
<PP&E>                                      60,973,410
<DEPRECIATION>                            (28,014,366)
<TOTAL-ASSETS>                              51,490,801
<CURRENT-LIABILITIES>                        1,721,838
<BONDS>                                     43,115,968
<COMMON>                                             0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<OTHER-SE>                                   3,965,658
<TOTAL-LIABILITY-AND-EQUITY>                51,490,801
<SALES>                                              0
<TOTAL-REVENUES>                            17,027,038
<CGS>                                                0
<TOTAL-COSTS>                               18,148,464
<OTHER-EXPENSES>                             (162,424)
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                           2,559,041
<INCOME-PRETAX>                            (2,118,917)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                        (2,118,917)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                               (2,118,917)
<EPS-PRIMARY>                                  (24.66)
<EPS-DILUTED>                                        0
        

</TABLE>
---

---

Exhibit 14.1



# CONSENT OF INDEPENDENT
REGISTERED PUBLIC ACCOUNTING FIRM

We
consent to the incorporation by reference in the Registration Statements Form S-8 (File
Nos.          333-102288 and 333-92491) pertaining to the Employee Stock Option plans of NUR
Macroprinters Ltd (the Company) and Form F-3 (File Nos. 333-115826, 333-114428, 333-47842 and
333-92493) of the Company of our report dated May 26, 2006, with respect to the consolidated financial
statements of the Company. included in this Annual Report on Form 20-F for the year ended December 31,
2005..

| |  | /s/ KOST FORER GABBAY & KASIERER
KOST FORER GABBAY & KASIERERA Member of Ernst & Young Global
| |  | ---------------------------------------------------------------------------------------------

Tel Aviv, IsraelJuly 16, 2006



---

---
----

| Dated:                 February 19, 2008 |   |
|----------------------------------------------------|--------|
|                                               |   |
| /s/                Alan Kiraly                     |   |
|                                               |   |
| Alan                Kiraly                         |   |
| Chief                Executive Officer             |   |

| Dated:                 February 19, 2008 |   |
|----------------------------------------------------|--------|
|                                               |   |
| /s/                John W. Low                     |   |
|                                               |   |
| John                W. Low                         |   |
| Chief                Financial Officer             |   |

----
<PAGE>   1
                                                                    EXHIBIT 23.2

               CONSENT OF ERNST & YOUNG LLP, INDEPENDENT AUDITORS



      We consent to the incorporation by reference in the Registration Statement
(Form S-8) pertaining to the SeaMED Corporation 1988 Stock Option Plan of our
report dated August 6, 1996, with respect to the financial statements and
schedule of SeaMED Corporation included in its Registration Statement, as
amended (Form S-1 No. 333-13455) filed with the Securities and Exchange
Commission on November 18, 1996.


Seattle, Washington                                   ERNST & YOUNG LLP
July 22, 1997
**Exhibit 32**

 

**CERTIFICATION**

 

The certifications set forth below are hereby submitted to theSecurities and Exchange Commission pursuant to, and solely for the purpose ofcomplying with, Section 1350 of Chapter 63 of Title 18 of the United StatesCode in connection with the filing on the date hereof with the Securities andExchange Commission of the Quarterly Report on Form 10-Q of the Company for thequarter ended June 30, 2004.

 

Each of the undersigned hereby certifies in his capacity as an officerof Citizens Bancshares Corporation and subsidiaries (the “Company”) that theQuarterly Report of the Company on Form 10-Q for the period ended June 30, 2004fully complies with the requirements of Section 13(a) of the SecuritiesExchange Act of 1934 and that the information contained in such report fairlypresents, in all material respects, the financial condition of the Company atthe end of such period and the results of operations of the Company for suchperiod.

 

 
| Date:  | August 13, 2004 | By:                                                          | /s/ James E. Young   |   |
|--------|-----------------|--------------------------------------------------------------|----------------------|--------|
|   |            | James E. Young                                               |
|   |            | President and Chief Executive Officer                        |
|   |            |                                                         |                 |
| Date:  | August 13, 2004 | By:                                                          | /s/ Willard C. Lewis |   |
|   |            | Willard C. Lewis                                             |
|   |            | Senior Executive Vice President and  Chief Operating Officer |
|   |            |                                                         |                 |
| Date:  | August 13, 2004 | By:                                                          | /s/ Samuel J. Cox    |   |
|   |            | Samuel J. Cox                                                |
|   |            | Senior Vice President and  Chief Financial Officer           |
|        |                 |                                                              |                      |        |  |  |

 

1

----
§ 310.200 Prescription-exemption procedure. ( a ) *Duration of prescription requirement.* Any drug limited to prescription use under section 503(b)(1)(B) of the act remains so limited until it is exempted as provided in paragraph (b) or (e) of this section.
( b ) *Prescription-exemption procedure for drugs limited by a new drug application.* Any drug limited to prescription use under section 503(b)(1)(B) of the act shall be exempted from prescription-dispensing requirements when the Commissioner finds such requirements are not necessary for the protection of the public health by reason of the drug's toxicity or other potentiality for harmful effect, or the method of its use, or the collateral measures necessary to its use, and he finds that the drug is safe and effective for use in self-medication as directed in proposed labeling. A proposal to exempt a drug from the prescription-dispensing requirements of section 503(b)(1)(B) of the act may be initiated by the Commissioner or by any interested person. Any interested person may file a petition seeking such exemption, which petition may be pursuant to part 10 of this chapter, or in the form of a supplement to an approved new drug application.
( c ) *New drug status of drugs exempted from the prescription requirement.* A drug exempted from the prescription requirement under the provisions of paragraph (b) of this section is a “new drug” within the meaning of section 201(p) of the act until it has been used to a material extent and for a material time under such conditions except as provided in paragraph (e) of this section.
( d ) *Prescription legend not allowed on exempted drugs.* The use of the prescription caution statement quoted in section 503(b) (4) of the act, in the labeling of a drug exempted under the provisions of this section, constitutes misbranding. Any other statement or suggestion in the labeling of a drug exempted under this section, that such drug is limited to prescription use, may constitute misbranding.
( e ) *Prescription-exemption procedure of OTC drug review.* A drug limited to prescription use under section 503(b)(1)(B) of the act may also be exempted from prescription-dispensing requirements by the procedure set forth in § 330.13 of this chapter.
[39 FR 11680, Mar. 29, 1974, as amended at 41 FR 32582, Aug. 4, 1976; 42 FR 4714, Jan. 25, 1977; 42 FR 15674, Mar. 22, 1977; 72 FR 15043, Mar. 30, 2007]
United States Court of Appeals

for the Federal Circuit ______________________ 

R+L CARRIERS, INC.,

Plaintiff-Appellant,

v.

PITT OHIO EXPRESS INC.,

Defendant-Appellee.

______________________ 

2012-1471

______________________ 

Appeal from the United States District Court for the 

Southern District of Ohio (Cincinnati) in No. 10-CV-0090, 

Judge Sandra S. Beckwith.

______________________ 

JUDGMENT

______________________ 

ANTHONY C. WHITE, Thompson Hine, LLP, of Columbus, Ohio, argued for plaintiff-appellant. With him on 

the brief were MEGAN D. DORTENZO, of Cleveland, Ohio, 

and STEPHEN J. BUTLER, of Cincinnati, Ohio. Of counsel 

was TROY S. PRINCE, of Cleveland, Ohio. 

GRETCHEN L. JANKOWSKI, Buchanan Ingersoll & 

Rooney, PC, of Pittsburgh, Pennsylvania, argued for 

defendant-appellee. With her on the brief was MICHAEL 

L. DEVER. 

______________________ 
THIS CAUSE HAVING BEEN HEARD AND CONSIDERED, IT IS

ORDERED AND ADJUDGED:

PER CURIAM (NEWMAN, PROST, and O’MALLEY, Circuit 

Judges).

AFFIRMED. See Fed. Cir. R. 36.

 ENTERED BY ORDER OF THE COURT

February 6, 2013 /s/ Jan Horbaly 

 Date Jan Horbaly

 Clerk
EXHIBIT 32.1


                            CERTIFICATION PURSUANT TO
                       18 U.S.C. SECTION 1350 (AS ADOPTED
                         PURSUANT TO SECTION 906 OF THE
                           SARBANES-OXLEY ACT OF 2002)

      In connection with the Quarterly Report of Factory 2-U Stores, Inc. (the
"Company") on Form 10-Q for the period ended May 1, 2004, as filed with the
Securities and Exchange Commission on the date hereof (the "Report"), I, Norman
G. Plotkin, Chief Executive Officer of the Company, certify to my knowledge and
in my capacity as an officer of the Company, pursuant to 18 U.S.C. 1350, as
adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

      1. The Report fully complies with the requirements of Section 13(a) or
15(d) of the Securities Exchange Act of 1934, as amended; and

      2. The information contained in the Report fairly presents, in all
material respects, the financial condition and results of operations of the
Company as of the dates and for the periods expressed in the Report.

      IN WITNESS WHEREOF, the undersigned has executed this Certificate,
effective as of June 10, 2004.


                                          /s/ Norman G. Plotkin
                                          ---------------------
                                          Norman G. Plotkin
                                          Chief Executive Officer


A signed original of this written statement required by Section 906 has been
provided to Factory 2-U Stores, Inc. and will be retained by Factory 2-U Stores,
Inc. and furnished to the Securities and Exchange Commission or its staff upon
request.
Michigan Supreme Court

Lansing, Michigan

Robert P. Young, Jr.

, Chief Justice

Michael F. Cavanagh

Stephen J. Markman

Mary Beth Kelly

Brian K. Zahra

Bridget M. McCormack

David F. Viviano

, Justices

I, Larry S. Royster , Clerk of the Michigan Supreme Court, certify that the

foregoing is a true and complete copy of the order entered at the direction of the Court.

June 24, 2014

s0616 

# Order

Clerk June 24, 2014

148461

PEOPLE OF THE STATE OF MICHIGAN,

Plaintiff

- Appellee,

v SC: 148461

COA: 318902

Kalamazoo CC: 2007

- 001823

- FC

BRUCE LEE PARKER,

Defendant

- Appellant.

_________________________________________/

On order of the Court, the application for leave to appeal the January 2, 2014 order

of the Court of Appeals is considered, and it is DENIED, because the defendant’s motion

for relief from judgment is prohibited by MCR 6.502(G).
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
UNAUDITED INTERIM DECEMBER 31, 1999 BALANCE SHEET AND STATEMENT OF OPERATIONS
OF FORCENERGY INC FOR THE YEAR ENDED DECEMBER 31, 1999 AND IS QUALIFIED IN ITS
ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-END>                               DEC-31-1999
<CASH>                                          96,506
<SECURITIES>                                         0
<RECEIVABLES>                                   41,332
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                               156,700
<PP&E>                                         512,000
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                                 675,401
<CURRENT-LIABILITIES>                          120,928
<BONDS>                                        314,473
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                           240
<OTHER-SE>                                     239,760
<TOTAL-LIABILITY-AND-EQUITY>                   675,401
<SALES>                                        265,824
<TOTAL-REVENUES>                               266,730
<CGS>                                                0
<TOTAL-COSTS>                                  221,621
<OTHER-EXPENSES>                               (62,959)
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              32,270
<INCOME-PRETAX>                                (50,120)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                            (50,120)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                159,972
<CHANGES>                                            0
<NET-INCOME>                                   109,852
<EPS-BASIC>                                       4.44
<EPS-DILUTED>                                     4.44


</TABLE>
#### § 21.74 Providing notice that a record is disputed.

Whenever an individual has filed a statement of disagreement with the Food and Drug Administration concerning a refusal to amend a record under § 21.51(a)(2) or with another agency that provides the record to the Food and Drug Administration, the Food and Drug Administration shall in any subsequent disclosure under this subpart provide a copy of the statement of disagreement and a concise statement by the agency, if one has been prepared, of the reasons for not making the amendment(s) requested.
#### Ripley et al. *v.*The Mutual Home and Savings Association et al.

[No. 18,718.

Filed February 2, 1900.]

Appeal and Eebob. — *Special*Judge.— Competency.— Objections.— *Waiver.*— Objections to the competency of a special judge to preside must be made at the time, or the right to object thereto will be waived.

Prom the Hendricks Circuit Court.

*Affirmed.*

*PL. J. Everett*and *C. PL. Everett,*for appellants.

*Elmer E. Stevenson,*for appellees.

Monks, J.

All the errors assigned by appellants, except the fifth, are predicated upon the theory that section 9 of *156the act of 1897 (Acts 1897, p. 287), §3406i Homer 1897, §4463i Burns Supp., was void, so far as it provides that all contracts theretofore made between borrowers and building and loan associations, for the payment of premiums without any bidding, are legalized. This question was decided in *International, etc., Assn.*v. *Wall,*153 Ind. 554, adversely to appellants’ theory and contention.

By the fifth error assigned appellants attempt to challenge the appointment of the special judge who tried said cause, on the ground that the person appointed was incompetent. The record shows that appellants filed an affidavit for change of judge in the court below, and that the person appointed to try said cause by the judge of said court was a competent and disinterested attorney of said court. No objection was made by anyone to said appointment, nor was it questioned in any manner in the court below. It is settled in this State that the only questions not waived by a failure to present the same in the court below, and that can be presented for the first time on appeal, are that the complaint does not state facts sufficient to constitute a cause of action, and want of jurisdiction over the subject-matter of the action. *Yorn*v. *Bracken,*153 Ind. 492; Elliott’s App. Proc., §§489, 674. Under this rule, objections to the competency of a special judge to preside must be made at the time, or the right to object thereto will be waived. *Lillie*v. *Trentman,*130 Ind. 16; *Cargar*v. *Fee,*119 Ind. 536; *Greenwood*v. *State,*116 Ind. 485; *Schlungger*v. *State,*113 Ind. 295; *Powell v. Powell,*104 Ind. 18; *Rogers*v. *Beauchamp,*102 Ind. 33; *Adams*v. *Gowan,*89 Ind. 358; *Huffman*v. *Cauble,*86 Ind. 591; *State*v. *Murdock,*86 Ind. 124; *Feaster*v. *Woodfill,*23 Ind. 493; *Case*v. *State,*5 Ind. 1.

Binding no available error in the record, the judgment is affirmed.
<PAGE>

                                                                   Exhibit 11.1

                         DIGITAL MICROWAVE CORPORATION
                       COMPUTATION OF PER SHARE EARNINGS
                   (In thousands, except per share amounts)
                                  (Unaudited)

<TABLE>
<CAPTION>

                                                  Three Months Ended      Nine Months Ended
                                                   December 31, 1997      December 31, 1997
                                                  ------------------      -----------------
                                                   1997        1996        1997        1996
                                                   ----        ----        ----        ----
<S>                                              <C>         <C>         <C>         <C>
Basic:
 Weighted average shares outstanding              38,009      32,194      37,634      31,941





Diluted:
 Weighted average shares outstanding              38,009      32,194      37,634      31,941
 Common stock equivalents                          1,832       1,925       1,981       1,334
                                                  ------      ------      ------      ------
                                                  39,841      34,119      39,615      33,275


Earnings per share:
 Basic                                            $  .23      $  .12      $  .59      $  .22
                                                  ------      ------      ------      ------
                                                  ------      ------      ------      ------
 Diluted                                          $  .22      $  .11      $  .56      $  .22
                                                  ------      ------      ------      ------
                                                  ------      ------      ------      ------

</TABLE>

All amounts adjusted for the two-for-one stock split of the Company's Common 
Stock, effected November 24, 1997, with 1996 amounts restated accordingly.
<PAGE>   1
                                                                      EXHIBIT 11






Statement Regarding Computation of Per Share Earnings

(in 000's, except per share amounts)
<TABLE>
<CAPTION>
                                                   Three Months Ended

                                                March 31,         April 1,
                                                  2001              2000
<S>                                            <C>                <C>
Weighted average shares outstanding              47,496             47,247

Effect of dilutive securities                         -                107

Shares for diluted EPS                           47,496             47,354


Net income (loss)                              ($26,083)            $1,301



Per share amounts:

  Basic                                         ($0.55)              $0.03


  Diluted                                       ($0.55)              $0.03

</TABLE>
<TABLE> <S> <C>

<ARTICLE>          5
<LEGEND>           THIS SCHEDULE CONTAINS SUMMARY FINANCIAL
                   INFORMATION EXTRACTED FROM THE 
                   COMPANY'S UNAUDITED FINANCIAL STATEMENTS
                   AS OF AND FOR THE PERIOD ENDING JUNE 28, 
                   1997, AND IS QUALIFIED IN ITS ENTIRETY BY 
                   REFERENCE TO SUCH FINANCIAL STATEMENTS 
<MULTIPLIER>       1,000
<FISCAL-YEAR-END>  JAN-3-1998
<PERIOD-END>       JUN-28-1997
<PERIOD-TYPE>      6-MOS


<CASH>                                              5,824
<SECURITIES>                                            0
<RECEIVABLES>                                     110,181
<ALLOWANCES>                                          489
<INVENTORY>                                        83,389
<CURRENT-ASSETS>                                  240,884
<PP&E>                                            193,672
<DEPRECIATION>                                     57,680
<TOTAL-ASSETS>                                    506,508
<CURRENT-LIABILITIES>                             212,551
<BONDS>                                                 0
<COMMON>                                           47,057
<PREFERRED-MANDATORY>                                   0
<PREFERRED>                                             0
<OTHER-SE>                                        198,257
<TOTAL-LIABILITY-AND-EQUITY>                      506,508
<SALES>                                           834,882
<TOTAL-REVENUES>                                  834,882
<CGS>                                             713,596
<TOTAL-COSTS>                                     713,596
<OTHER-EXPENSES>                                        0
<LOSS-PROVISION>                                        0
<INTEREST-EXPENSE>                                    769
<INCOME-PRETAX>                                    53,339
<INCOME-TAX>                                       21,300
<INCOME-CONTINUING>                                32,039
<DISCONTINUED>                                          0
<EXTRAORDINARY>                                         0
<CHANGES>                                               0
<NET-INCOME>                                       32,039
<EPS-PRIMARY>                                        0.65
<EPS-DILUTED>                                        0.65



</TABLE>